Lazard Asset Management LLC lifted its stake in shares of LivaNova PLC (NASDAQ:LIVN - Free Report) by 145.1% in the fourth quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 35,156 shares of the company's stock after buying an additional 20,813 shares during the quarter. Lazard Asset Management LLC owned approximately 0.06% of LivaNova worth $1,628,000 at the end of the most recent reporting period.
A number of other institutional investors and hedge funds have also made changes to their positions in LIVN. Freestone Grove Partners LP acquired a new position in shares of LivaNova during the fourth quarter worth about $23,102,000. Artisan Partners Limited Partnership acquired a new position in shares of LivaNova during the fourth quarter worth about $21,340,000. The Manufacturers Life Insurance Company grew its position in shares of LivaNova by 163.6% during the fourth quarter. The Manufacturers Life Insurance Company now owns 546,387 shares of the company's stock worth $25,303,000 after buying an additional 339,139 shares in the last quarter. AQR Capital Management LLC grew its position in shares of LivaNova by 79.3% during the fourth quarter. AQR Capital Management LLC now owns 742,180 shares of the company's stock worth $34,214,000 after buying an additional 328,313 shares in the last quarter. Finally, Vanguard Group Inc. grew its position in shares of LivaNova by 12.7% during the fourth quarter. Vanguard Group Inc. now owns 2,349,887 shares of the company's stock worth $108,823,000 after buying an additional 265,291 shares in the last quarter. 97.64% of the stock is owned by institutional investors and hedge funds.
Wall Street Analysts Forecast Growth
A number of brokerages have recently commented on LIVN. Stifel Nicolaus lowered their price objective on LivaNova from $72.00 to $60.00 and set a "buy" rating for the company in a research report on Wednesday, February 26th. The Goldman Sachs Group lowered their price target on LivaNova from $64.00 to $55.00 and set a "buy" rating for the company in a report on Monday, March 3rd. Robert W. Baird upped their price target on LivaNova from $55.00 to $61.00 and gave the company an "outperform" rating in a report on Thursday, May 8th. Barclays lowered their price target on LivaNova from $56.00 to $55.00 and set an "equal weight" rating for the company in a report on Thursday, May 8th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $64.00 price target on shares of LivaNova in a report on Tuesday, May 13th. Two analysts have rated the stock with a hold rating, six have assigned a buy rating and one has issued a strong buy rating to the company. Based on data from MarketBeat, LivaNova presently has a consensus rating of "Moderate Buy" and an average target price of $59.17.
Check Out Our Latest Report on LivaNova
LivaNova Stock Performance
Shares of LIVN opened at $44.40 on Monday. The stock has a 50 day moving average price of $38.39 and a 200 day moving average price of $44.81. The company has a quick ratio of 2.87, a current ratio of 3.37 and a debt-to-equity ratio of 0.46. The company has a market capitalization of $2.42 billion, a price-to-earnings ratio of 105.71 and a beta of 0.84. LivaNova PLC has a 52-week low of $32.48 and a 52-week high of $62.04.
About LivaNova
(
Free Report)
LivaNova PLC, a medical device company, designs, develops, manufactures, and sells therapeutic solutions worldwide. The company operates through Cardiopulmonary, Neuromodulation, and Advanced Circulatory Support segments. The Cardiopulmonary segment develops, produces, and sells cardiopulmonary products, including oxygenators, heart-lung machines, autotransfusion systems, perfusion tubing systems, cannulae, connect, and other related products.
Featured Stories
Want to see what other hedge funds are holding LIVN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for LivaNova PLC (NASDAQ:LIVN - Free Report).
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider LivaNova, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and LivaNova wasn't on the list.
While LivaNova currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering where to start (or end) with AI stocks? These 10 simple stocks can help investors build long-term wealth as artificial intelligence continues to grow into the future.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
